Top

Skeletal Radiology

Published in:

01-03-2003 | Article

FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses

Authors: J. Aoki, H. Watanabe, T. Shinozaki, K. Takagishi, M. Tokunaga, Y. Koyama, N. Sato, K. Endo

Published in: Skeletal Radiology | Issue 3/2003

Abstract

Objective

To evaluate the standardized uptake value (SUV) of [¹⁸F]2-deoxy-2-fluoro-d-glucose at positron emission tomography (FDG-PET) for preoperative differential diagnosis between benign and malignant soft tissue masses.

Design

One hundred and fourteen soft tissue masses (80 benign, 34 malignant) were examined by FDG-PET prior to tissue diagnosis. The SUVs were calculated and compared between benign and malignant lesions and among different histologic subgroups which included three or more cases.

Results

There was a statistically significant difference in SUV between benign (1.80±1.42 [SD]) and malignant (4.20±3.16) soft tissue masses in total (P<0.0001). However, a considerable overlap in SUV was observed between many benign and malignant lesions. Liposarcomas (2.16±1.72) and synovial sarcomas (1.60±0.43) did not show significantly higher SUV than any benign lesions. Metastases (4.23±2.35) showed no statistically significant difference in SUV as compared with schwannomas (1.75±0.84), desmoids (2.77±1.32), sarcoidosis (3.62±1.53), or giant cell tumors of tendon sheath (GCT of TS; 5.06±1.63). Even malignant fibrous histiocytomas (5.37±1.40) could not be differentiated from sarcoidosis or GCT of TS, based on the SUV.

Conclusions

A large accumulation of FDG can be observed in both benign and malignant histiocytic, fibroblastic, or neurogenic lesions. SUV at conventional FDG-PET is limited to differentiating benign from malignant soft tissue masses, when all kinds of histologic subtypes are included.

Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of soft tissue masses. An evaluation of fifty-three histologically proven tumors. Magn Reson Imaging 1988; 6:237–248.PubMed

Kransdorf MJ, Murphey MD. Imaging of soft tissue tumors. In: Kransdorf MJ, Murphey MD, eds. Imaging of soft tissue tumors. Philadelphia: Saunders, 1997:37–56.

Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94–106.PubMed

Brock CS, Meikle SR, Price P. Dose fluorine-18 fluorodeoxyglucose metabolic imaging of tumors benefit oncology? Eur J Nucl Med 1997; 24:691–705.CrossRefPubMed

Bar-Shalon R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30:150–185.PubMed

Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181–186.PubMed

Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-d-glucose. Radiology 1992; 182:185–194.PubMed

Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508–1512.PubMed

Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257–261.PubMed

10.

Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 1999; 231: 380–386.CrossRef

11.

Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86:550-556.CrossRefPubMed

12.

Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of non-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed

13.

Meikle SR, Bailey DL, Hooper PK, et al. Simultaneous emission and transmission measurement for attenuation correction in whole-body PET. J Nucl Med 1995; 36:1680–1688.PubMed

14.

Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with PET-FDG. J Nucl Med 1995; 36:788–793.PubMed

15.

Watanabe H, Shinozaki T, Yanagawa T, et al. Glucose metabolic analysis of musculoskeletal tumors using¹⁸fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000; 82:760–767.PubMed

16.

Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumors with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 flurodeoxyglucose PET. Eur J Nucl Med 2000; 27:1509–1517.CrossRefPubMed

17.

Lodge MA, Lucus JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of¹⁸FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22–30.CrossRefPubMed

18.

Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, et al. Dynamic PET¹⁸F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42:713–720.PubMed

19.

Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 1987; 262:10965–10970.PubMed

20.

Gamelli RL, Liu H, He L, Hofmann CA. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639–647.PubMed

21.

Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 1995; 196:647–655.PubMed

22.

Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749–754.PubMed

23.

Brudin LH, Valid S-O, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297–305.PubMed

24.

Yamada Y, Uchida Y, Tatsumi K, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39:1160–1166.PubMed

25.

Aoki J, Watanabe H, Shinozaki T, et al. FDG-PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774–777.PubMed

26.

Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue (editorial). J Nucl Med 1993; 34:419–421.PubMed

27.

Magnani P, Cherian PV, Gould GW, Greene DA, Sima AAF, Brosius FC. Glucose transporters in rat peripheral nerve: paranodal expression of GLUT1 and GLUT3. Metabolism 1996; 45:1466–1473.PubMed

Title: FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses
Authors: J. Aoki
H. Watanabe
T. Shinozaki
K. Takagishi
M. Tokunaga
Y. Koyama
N. Sato
K. Endo
Publication date: 01-03-2003
Publisher: Springer-Verlag
Published in: Skeletal Radiology / Issue 3/2003
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI: https://doi.org/10.1007/s00256-002-0586-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses

Abstract

Objective

Design

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Design

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2003

The acrophysis: a unifying concept for enchondral bone growth and its disorders. I. Normal growth

Leiomyosarcoma of the popliteal vein

MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign

Malignancy in giant cell tumor

Giant cell reparative granuloma of the occipital bone

Low-grade osteosarcoma of the maxillary sinus